Skip to main content
. 2021 May 21;321(1):H29–H37. doi: 10.1152/ajpheart.01023.2020

Figure 4.

Figure 4.

Change in percent dilation at maximal pressure gradient (Δ100 cmH2O) with and without inhibitors at normal and high intraluminal pressures (% dilation without inhibitor at Δ100 cmH2O − % dilation with inhibitor at Δ100 cmH2O). A: Δ% dilation before and after incubation with l-NAME at normal intraluminal pressure (60 cmH2O; ns, not significant). B: Δ% dilation before and after incubation with l-NAME at high intraluminal pressure (150 cmH2O; ns, not significant). C: Δ% dilation before and after incubation with PEG-cat at normal intraluminal pressure (60 cmH2O; *P < 0.05). D: Δ% dilation before and after incubation with PEG-cat at high intraluminal pressure (150 cmH2O; ns, not significant). Data are means ± SE. l-NAME, NG-nitro-l-arginine methyl ester; ns, not significant; PEG-cat, polyethylene glycol-catalase.